In general, NRF2 is dysregulated in many tumors, thereby leading to the radioresistance during cancer therapy.34 Moreover, targeting NRF2 has been validated to be an exciting strategy for the radiosensitization by increasing ROS generation.35,36 Thus, we suppose that HACE1 decreases the radiosensitivity of glioma cells probably via NRF2 activation. The gene discussed is NFE2L2; the disease is cancer.